GlobeNewswire by notified

Company announcement no 18/2022 - Interim Report Q3 2022


Interim Report Q3 2022

EBITDA fixed herd prices (FHP) for Q3 2022 increased to 10,463 kEUR (Q3 2021: 7.536 kEUR), corresponding to an EBITDA margin FHP of
32.5% (Q1 2021: 28.2%). The quarterly EBITDA in Q3 2022 increased by 2.927 kEUR (compared to Q3 2021).  Main factors where higher subsidy increased 1,1 mEUR and improved Lithuanian contribution from improved sales price and feed price ratio of EUR 4,3m, whereas negative factors being Harvest -0,6 mEUR and lower volume from Ostrov estimated to -1,5 mEUR (expected fully normalized in Q1 2023).

Sales prices in Q2 were 1.62 EUR/kg live weight, up from 1,18 EUR/kg (Q3 2021). Better prices have been driven by the price increase in LT, which increased by 0,49 EUR/kg compared to 2021 (or 48%).

Feed prices in Q3 2022 were 302 EUR/T (compared to 249 EUR/T Q3 2021). The price increases do not reflect market, as spot market price increases is significant higher. Idavang going forward has limited grain contract fixed on price, but have 6,7 mEUR profit for 2022/2023 harvest in the equity (hence reducing cost per T with approximate 64 EUR in Lithuania) during the next 12 months. 

Subsidy increased with 1,1 mEUR due to subsidy in LT for high feed prices of 2,5 mEUR in Q3 2022 (and is not expected in the future), compared to 1,4 mEUR in Q3 2021 in LT/RU.

Cash flow EBITDA (without matif) in Lithuania is currently around 1,43-1,45 EUR (up from Q2 1,33-1,35 EUR), and utility prices is driving around than half of the increase. 

The herd valuation in Q3 increased by 3,227 kEUR (compared to 30.06.2022). The increase is driven by increasing prices in EU as effect of reductions in production of pork in EU.

Net interest-bearing debt (NIBD) decreased to EUR 71.0m in Q3 2022, being EUR 8.4m lower than in Q4 2021 (78.5 mEUR), mainly due to subsidies received 5,1 mEUR and matif gain realized.

EURRUB exchange rate
Idavang have chosen to use the official FX rates from Central bank of Russia due to input from auditors.  Q2 have been restated.
Impact of this is significant as RUB as value increase 52% since 31.12.2021.


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Amlan International Adds Sales Manager, Distribution Partner and is Granted New Registration of Calibrin-Z in the Philippines29.11.2022 22:41:20 CET | Press release

CHICAGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Amlan International, the animal health business of Oil-Dri® Corporation of America, is pleased to announce exciting new developments for their business in the Philippines. Jayson Fernandez joined Amlan as a sales manager for the Philippines in January 2022 and FJ Wegon Animal Health and Nutrition Inc. is now registered to distribute proven biotoxin binder Calibrin®-Z. Registration is pending of additional high-value feed additives, such as patented Varium®, designed for poultry feed efficiency. The Philippines is the fourth-largest poultry producer in Southeast Asia, producing 1.4 million tons of broiler meat in 2020, and the third-largest swine producer in Asia, producing 1.5 million tons of pork meat. However, these production achievements have not been without challenges. The poultry industry is still recovering from COVID-19 disruptions, and swine repopulation efforts are continuing after African swine fever outbreaks. “As producers in the

Conagen develops high-purity non-GMO sulforaphane by bioconversion29.11.2022 21:23:38 CET | Press release

Commercial production is underway for 2023. Bedford, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Expanding on its portfolio of innovative nutritional products through biotechnology, Conagen, announced the development of its 99% high-purity sulforaphane. Made by a proprietary bioconversion technology, the company plans to begin the commercialization path in 2023. Conagen’s bioconversion methods enable the production of sustainable products from many naturally occurring compounds regardless of rarity or small quantities occurring in nature. “As a supplement product, Conagen’s high-purity sulforaphane is appealing to consumers as the levels found in raw vegetables are too low to realize many of its promising health benefits,” said Casey Lippmeier, Ph.D., senior vice president of innovation. “We’re looking forward to expanding the nutritional market by commercializing sulforaphane in 2023.” Sulforaphane has been associated with supporting health benefits against cancer, diabetes, digestion, a

Yara’s employee share purchase program and mandatory notification of trades29.11.2022 19:02:00 CET | Press release

Oslo, 29 November 2022: The Foundation for employees’ shares in Yara (“Stiftelsen For Ansattes Aksjer i Yara”) has today purchased a total of 34,000 Yara shares (ticker: YAR, ISIN: NO0010208051) in the market at an average price of NOK 463.9398 per share, as part of Yara’s employee share purchase program in Norway. Permanent Yara employees in Norway can take part in the annual offer to buy Yara shares for a value of either NOK 7,500, NOK 15,000 or NOK 30,000. Based on the three alternatives, Yara employees purchased either 16 Yara shares, 32 Yara shares or 64 Yara shares at NOK 466.40 per share. In total, Yara employees purchased 33,264 Yara shares from the Foundation for employees’ shares in Yara. A total of 605 employees participated in the program. Following these transactions, the Foundation for employees’ shares in Yara owns 748 Yara shares. The share purchases linked to the employee share purchase program by the following Yara Board members are considered as PDMR trades under the

Rovio Entertainment Corporation: Repurchase of own shares on 29 November 202229.11.2022 17:45:00 CET | Press release

Rovio Entertainment Oyj STOCK EXCHANGE RELEASE 29.11.2022 at 18.45 EETRovio Entertainment Corporation - Repurchase of own shares on 29.11.2022Rovio Entertainment CorporationIn the Nasdaq HelsinkiDate29.11.2022Exchange transactionBUYShare trading codeROVIOAmount, shares27148Average price/share, EUR5,942434Total cost, EUR161325,20Rovio now holds a total of 6 382 613 shares including the shares repurchased on 29.11.2022On behalf of Rovio Entertainment CorporationOP Corporate Bank PLC Further information: Timo Rahkonen, VP Investor Relations & Corporate Strategy +358 40 730 3442 Distribution: Nasdaq Helsinki Ltd Key media About Rovio: Rovio Entertainment Corporation is a global mobile-first games company that creates, develops and publishes mobile games, which have been downloaded over 5 billion times. Rovio is best known for the global Angry Birds brand, which started as a popular mobile game in 2009, and has since evolved from games to various entertainmen